Brand Name: Tecentriq Generic Name: (Atezolizumab)
Tecentriq (Atezolizumab) is used to treat patients with locally advanced or metastatic urothelial carcinoma
TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy, and whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 5% of the tumor area), or are not eligible for any platinum-containing chemotherapy regardless of level of tumor PD-L1 expression, or have disease progression during or following any platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy.
| Brand Name: | Tecentriq |
| Generic Name: | Atezolizumab |
| Strength: | Injection: 1200 mg/20 mL (60 mg/mL) solution in a single-dose vial. |
| Manufacturer: | Genentech |
| Approved By: | EMA, USFDA |
Source Details: Patient Information
IPN, New Delhi can facilitate patient to import of “Tecentriq (Atezolizumab)” in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP). If you have any question, please email IPN healthcare Support Team for Tecentriq (Atezolizumab) price list or cost in India. on Mr. Tarun:- +91 9891 296 838 / Mr. Neeraj:- +91 9811 747 774.
